Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R McKay

Showing results (771-780 of 932) with videos related to

Pageof 94
Sort By:
Journal for Immunotherapy of Cancer|March 23, 2026
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0Rana R McKay, Archana Ajmera, Michael B Atkins, et al.
Cancer Cell|November 22, 2024
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activationDavid Hsiehchen, Andrew Elliott, Joanne Xiu, et al.
Cancer Immunology Research|February 14, 2018
Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse EventsDylan J Martini, Lana Hamieh, Rana R McKay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2021
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 StudySumanta K Pal, Bradley McGregor, Cristina Suárez, et al.
Clinical Genitourinary Cancer|November 21, 2022
Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell CarcinomaAkram M Shayeb, Hannah Dzimitrowicz McManus, Danielle Urman, et al.
Cancer|November 20, 2020
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignanciesBradley Alexander McGregor, Matthew T Campbell, Wanling Xie, et al.
Iscience|December 11, 2020
An <i>In Vitro</i> Whole-Organ Liver Engineering for Testing of Genetic TherapiesMaëlle Lorvellec, Alessandro Filippo Pellegata, Alice Maestri, et al.
The Journal of Infectious Diseases|April 30, 2021
Activating Killer-Cell Immunoglobulin-Like Receptors Are Associated With the Severity of Coronavirus Disease 2019Enrique Bernal, Lourdes Gimeno, María J Alcaraz, et al.
European Urology|August 22, 2013
Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapyRana R McKay, Nils Kroeger, Wanling Xie, et al.
JCO Global Oncology|May 29, 2026
Prostate Cancer Treatment Patterns and Inequities Among Racial Groups in Brazil's Public Health System: Insights From a 16-Year Real-World StudyDaniel Herchenhorn, Haonne Abboud, Vinicius Freire, et al.
Pageof 94

Showing results (771-780 of 932) with videos related to

Sort By:
Pageof 94
Journal for Immunotherapy of Cancer|March 23, 2026
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0Rana R McKay, Archana Ajmera, Michael B Atkins, et al.
Cancer Cell|November 22, 2024
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activationDavid Hsiehchen, Andrew Elliott, Joanne Xiu, et al.
Cancer Immunology Research|February 14, 2018
Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse EventsDylan J Martini, Lana Hamieh, Rana R McKay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2021
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 StudySumanta K Pal, Bradley McGregor, Cristina Suárez, et al.
Clinical Genitourinary Cancer|November 21, 2022
Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell CarcinomaAkram M Shayeb, Hannah Dzimitrowicz McManus, Danielle Urman, et al.
Cancer|November 20, 2020
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignanciesBradley Alexander McGregor, Matthew T Campbell, Wanling Xie, et al.
Iscience|December 11, 2020
An <i>In Vitro</i> Whole-Organ Liver Engineering for Testing of Genetic TherapiesMaëlle Lorvellec, Alessandro Filippo Pellegata, Alice Maestri, et al.
The Journal of Infectious Diseases|April 30, 2021
Activating Killer-Cell Immunoglobulin-Like Receptors Are Associated With the Severity of Coronavirus Disease 2019Enrique Bernal, Lourdes Gimeno, María J Alcaraz, et al.
European Urology|August 22, 2013
Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapyRana R McKay, Nils Kroeger, Wanling Xie, et al.
JCO Global Oncology|May 29, 2026
Prostate Cancer Treatment Patterns and Inequities Among Racial Groups in Brazil's Public Health System: Insights From a 16-Year Real-World StudyDaniel Herchenhorn, Haonne Abboud, Vinicius Freire, et al.
Pageof 94